Marinomed Biotech AG
VSE:MARI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
18.2
19.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Wall Street
Price Targets
MARI Price Targets Summary
Marinomed Biotech AG
According to Wall Street analysts, the average 1-year price target for MARI is 52.02 EUR with a low forecast of 51.51 EUR and a high forecast of 53.55 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is MARI's stock price target?
Price Target
52.02
EUR
According to Wall Street analysts, the average 1-year price target for MARI is 52.02 EUR with a low forecast of 51.51 EUR and a high forecast of 53.55 EUR.
What is Marinomed Biotech AG's Revenue forecast?
Projected CAGR
81%
For the last 7 years the compound annual growth rate for Marinomed Biotech AG's revenue is 0%. The projected CAGR for the next 4 years is 81%.
